2024-03-28T14:21:26Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_6ADD45556097
2024-03-23T02:29:41Z
openaire
documents
urnserval
serval:BIB_6ADD45556097
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
10.1161/JAHA.117.006537
000418943800023
29122809
Gencer
B.
author
Koskinas
K.C.
author
Räber
L.
author
Karagiannis
A.
author
Nanchen
D.
author
Auer
R.
author
Carballo
D.
author
Carballo
S.
author
Klingenberg
R.
author
Heg
D.
author
Matter
C.M.
author
Lüscher
T.F.
author
Rodondi
N.
author
Mach
F.
author
Windecker
S.
author
article
2017-11-09
Journal of the American Heart Association
2047-9980
2047-9980
journal
6
11
NA
Acute Coronary Syndrome/blood
Acute Coronary Syndrome/drug therapy
Anticholesteremic Agents/administration & dosage
Apoptosis
Cardiology
Cholesterol, LDL/blood
Dose-Response Relationship, Drug
Eligibility Determination/methods
Europe
Ezetimibe/administration & dosage
Female
Follow-Up Studies
Humans
Male
Middle Aged
Practice Guidelines as Topic
Proprotein Convertase 9/antagonists & inhibitors
Prospective Studies
Societies, Medical
Time Factors
Treatment Outcome
United States
PCSK9
lipids
secondary prevention
eng
60_published
true
peer-reviewed
Publication types: Journal Article ; Multicenter Study ; Observational Study
Publication Status: epublish
https://serval.unil.ch/notice/serval:BIB_6ADD45556097
https://serval.unil.ch/resource/serval:BIB_6ADD45556097.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_6ADD455560971
Creative Commons : Attribution-NonCommercial 4.0 International